Matches in Wikidata for { <http://www.wikidata.org/entity/Q37121517> ?p ?o ?g. }
- Q37121517 description "article científic" @default.
- Q37121517 description "article scientifique" @default.
- Q37121517 description "articolo scientifico" @default.
- Q37121517 description "artigo científico" @default.
- Q37121517 description "artículu científicu espublizáu en 2013" @default.
- Q37121517 description "bilimsel makale" @default.
- Q37121517 description "scientific article published on 07 August 2013" @default.
- Q37121517 description "vedecký článok" @default.
- Q37121517 description "vetenskaplig artikel" @default.
- Q37121517 description "videnskabelig artikel" @default.
- Q37121517 description "vědecký článek" @default.
- Q37121517 description "wetenschappelijk artikel" @default.
- Q37121517 description "wissenschaftlicher Artikel" @default.
- Q37121517 description "наукова стаття, опублікована в серпні 2013" @default.
- Q37121517 description "научни чланак" @default.
- Q37121517 description "مقالة علمية نشرت في 07 أغسطس 2013" @default.
- Q37121517 name "Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer" @default.
- Q37121517 name "Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer" @default.
- Q37121517 name "Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer" @default.
- Q37121517 type Item @default.
- Q37121517 label "Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer" @default.
- Q37121517 label "Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer" @default.
- Q37121517 label "Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer" @default.
- Q37121517 prefLabel "Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer" @default.
- Q37121517 prefLabel "Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer" @default.
- Q37121517 prefLabel "Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer" @default.
- Q37121517 P1433 Q37121517-31916653-75A4-405C-8F62-C8DA73A87A51 @default.
- Q37121517 P1476 Q37121517-81030A0A-1C0A-4B2A-8490-7BB80574B43A @default.
- Q37121517 P2093 Q37121517-939EB146-13AE-4F68-8798-59DCBECCD95B @default.
- Q37121517 P275 Q37121517-b9885bc2-9082-4717-a1d4-00f8c01d416f @default.
- Q37121517 P2860 Q37121517-0EA0F3BF-FC1E-4EE4-8C48-09764DE2FC77 @default.
- Q37121517 P2860 Q37121517-149558BD-07CF-4007-A6FC-1EFCF7C892C9 @default.
- Q37121517 P2860 Q37121517-2D93C3C7-169D-41AD-B9D1-269B0F865DD8 @default.
- Q37121517 P2860 Q37121517-34F20F64-E169-4DAF-9F52-6D1C2C99BB89 @default.
- Q37121517 P2860 Q37121517-35AA3370-066E-4D43-AD8D-710D22BB5541 @default.
- Q37121517 P2860 Q37121517-5079C267-F7AF-4E23-AB8D-052F45931249 @default.
- Q37121517 P2860 Q37121517-5E636059-D363-480C-948E-68AABC86DA3D @default.
- Q37121517 P2860 Q37121517-7290B4ED-71FA-4A8A-BF96-59336551F597 @default.
- Q37121517 P2860 Q37121517-746FEA3B-C190-48D9-AC4C-74777D66CD0F @default.
- Q37121517 P2860 Q37121517-7DF04341-2ABD-4CD1-A3CC-C0E0AB885B8E @default.
- Q37121517 P2860 Q37121517-8B6BB66D-B8D3-45C1-BBAF-6EF47FCF8088 @default.
- Q37121517 P2860 Q37121517-8CD6C037-994F-49DC-8D94-1693BDAE3991 @default.
- Q37121517 P2860 Q37121517-9F8FCEC2-9517-4B5E-9A31-5E39E1C2954D @default.
- Q37121517 P2860 Q37121517-A4DC4606-0999-4278-B5DF-F8EA3D8C1C44 @default.
- Q37121517 P2860 Q37121517-B34AA190-767C-4447-9E06-0AD5FA1407E3 @default.
- Q37121517 P2860 Q37121517-B5889989-4961-4213-944D-CC62252E5947 @default.
- Q37121517 P2860 Q37121517-D0779569-DDBF-4696-A0B6-FC0FD2B37E12 @default.
- Q37121517 P2860 Q37121517-D11B6551-9C93-4D93-ADD8-2675B4373296 @default.
- Q37121517 P2860 Q37121517-FAF5AD1B-C9BE-4C77-97D1-48510A73076A @default.
- Q37121517 P2860 Q37121517-FF9465F4-A5D5-4FEE-9D21-A16057BEEEC0 @default.
- Q37121517 P2888 Q37121517-5D2A4578-8E43-452F-B22D-61CFE037DE7F @default.
- Q37121517 P304 Q37121517-641B7204-F37A-4414-BA9C-8AD4487335B6 @default.
- Q37121517 P31 Q37121517-53916BD6-C80C-4D2B-8014-52A7773A0BF5 @default.
- Q37121517 P356 Q37121517-5FB204DA-D346-41ED-BC44-CF3D6C89D309 @default.
- Q37121517 P433 Q37121517-BD304FA3-07EE-4357-9FB0-C0A1480E650E @default.
- Q37121517 P478 Q37121517-8FDCC2E5-8828-4641-9FBD-B5F279116681 @default.
- Q37121517 P50 Q37121517-229DCF2C-3F27-4DA3-9253-71AD676ADC60 @default.
- Q37121517 P50 Q37121517-518423B1-954D-49E2-ADD0-9089E737300B @default.
- Q37121517 P50 Q37121517-6486CE06-442D-44DC-9CB7-84EC5CA2B46A @default.
- Q37121517 P50 Q37121517-695036FC-0826-4190-B156-DDF31A2B7946 @default.
- Q37121517 P50 Q37121517-6E0697BB-4284-4B4D-9202-D964B83A0654 @default.
- Q37121517 P50 Q37121517-97E45AF2-5E56-4C99-8DD5-4AAA42461B11 @default.
- Q37121517 P50 Q37121517-AC80B65E-1264-4108-A27B-8F71BDE94825 @default.
- Q37121517 P50 Q37121517-D45D3E7B-2262-4DA8-8FB5-8C5A6AC18D68 @default.
- Q37121517 P50 Q37121517-D45FFC98-74CF-427C-8B67-098E8735C3B2 @default.
- Q37121517 P577 Q37121517-51863458-3CB8-470B-94BF-A77B45E97C30 @default.
- Q37121517 P5875 Q37121517-C670C144-FCD6-4734-944E-1BB6B46169F4 @default.
- Q37121517 P6216 Q37121517-673c3e25-5cb4-49dc-a5a2-0f4686cb6b29 @default.
- Q37121517 P698 Q37121517-DB3E5417-DBA5-4BC6-8BA4-BA4C5FC4CD0E @default.
- Q37121517 P921 Q37121517-428F9FB9-B8CD-47F8-B75F-E6B4D14AE2DD @default.
- Q37121517 P921 Q37121517-64F3731C-BC21-4D8D-85EF-818550D3C2ED @default.
- Q37121517 P921 Q37121517-9A90D71E-4ECD-4378-9086-6868758CAF91 @default.
- Q37121517 P921 Q37121517-9CA5D7B9-8FD5-4446-B57A-7029F9497E92 @default.
- Q37121517 P921 Q37121517-B7CFEE43-03B7-4EB6-9B87-937DA448E2CC @default.
- Q37121517 P921 Q37121517-DEDE6C76-8487-4FD9-818D-5B62A318C8C1 @default.
- Q37121517 P932 Q37121517-4EA063FB-01B0-463F-825E-52D3C9380C95 @default.
- Q37121517 P356 S00280-013-2240-8 @default.
- Q37121517 P698 23921573 @default.
- Q37121517 P1433 Q326137 @default.
- Q37121517 P1476 "Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer" @default.
- Q37121517 P2093 "Hwa-Ping Feng" @default.
- Q37121517 P275 Q19125117 @default.
- Q37121517 P2860 Q27824867 @default.
- Q37121517 P2860 Q27851454 @default.
- Q37121517 P2860 Q28189472 @default.
- Q37121517 P2860 Q28240089 @default.
- Q37121517 P2860 Q28272038 @default.
- Q37121517 P2860 Q29616236 @default.
- Q37121517 P2860 Q33391425 @default.
- Q37121517 P2860 Q35036376 @default.
- Q37121517 P2860 Q36615856 @default.
- Q37121517 P2860 Q37309022 @default.
- Q37121517 P2860 Q37658881 @default.
- Q37121517 P2860 Q44766752 @default.
- Q37121517 P2860 Q45073541 @default.
- Q37121517 P2860 Q46331071 @default.
- Q37121517 P2860 Q46624336 @default.
- Q37121517 P2860 Q47637332 @default.
- Q37121517 P2860 Q54570192 @default.
- Q37121517 P2860 Q62992251 @default.